EpiSafe

Epinephrine is the only thing that stops anaphylaxis — and it only works if it's on you when seconds matter. Yet more than half of people prescribed an auto-injector don't have it when they need it.

The reason is mundane and human: the standard injector is bulky, awkward, and easy to leave behind. The device isn't failing in the ER; it's failing in the pocket that stayed home.

EpiSafe's bet is simple — put the dose where the phone already is. If it lives in the one thing nobody forgets, carry rates change.

The internal injector was redesigned from scratch to fit a phone-case envelope — spring force, fluid path, and needle deployment all reworked to hit dose equivalence in a fraction of the thickness.

CAD is complete, and CFD simulations are validating dose delivery against a predicate auto-injector. Provisional patents are filed on both the mechanism and the form factor, and a companion iOS app is already on TestFlight for closed beta.

EpiSafe mounts to the back of a phone like a thin case insert. In an emergency the user — or a bystander — deploys it with a single action, delivering a 0.3 mg intramuscular dose the same way a conventional auto-injector does.

The companion app handles the parts software is good at: expiry reminders, location, and alerting an emergency contact the moment the device is used. The hardware stays dead-simple; the phone does the thinking.

The whole design is shaped by one constraint above all others — it has to earn FDA clearance. Every decision is made against the 510(k) substantial-equivalence pathway.

Next: bench testing for dose equivalence, a manufacturable industrial design, and an FDA pre-submission targeted for Q4 2026. The north star hasn't moved — make epinephrine something people actually have on them.